Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibiotic Resistance in Patients with Cystic Fibrosis: Past, Present, and Future
Evanthia Perikleous, Despoina Gkentzi, Aris Bertzouanis, et al.
Antibiotics (2023) Vol. 12, Iss. 2, pp. 217-217
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Investigating Biofilms: Advanced Methods for Comprehending Microbial Behavior and Antibiotic Resistance
Ahmad Almatroudi
Frontiers in Bioscience-Landmark (2024) Vol. 29, Iss. 4, pp. 133-133
Open Access | Times Cited: 13
Neutralizing antibodies after nebulized phage therapy in cystic fibrosis patients
Mireia Bernabéu-Gimeno, Marco Pardo-Freire, Benjamin K. Chan, et al.
Med (2024) Vol. 5, Iss. 9, pp. 1096-1111.e6
Open Access | Times Cited: 11
Doxycycline post-exposure prophylaxis could theoretically select for resistance to various antimicrobials in 19 pathobionts: an in silico analysis
Chris Kenyon
International Journal of Infectious Diseases (2024) Vol. 142, pp. 106974-106974
Open Access | Times Cited: 10
New Antimicrobial Strategies to Treat Multi-Drug Resistant Infections Caused by Gram-Negatives in Cystic Fibrosis
Viola Camilla Scoffone, Giulia Barbieri, Samuele Irudal, et al.
Antibiotics (2024) Vol. 13, Iss. 1, pp. 71-71
Open Access | Times Cited: 7
Bacterial Persister Cells and Development of Antibiotic Resistance in Chronic Infections: An Update
Anil Philip Kunnath, Mohamed Suodha Suoodh, Dinesh Kumar Chellappan, et al.
British Journal of Biomedical Science (2024) Vol. 81
Open Access | Times Cited: 7
Antibiotic loaded inhalable liposomal nanoparticles against lower respiratory tract infections: Challenges, recent advances, and future perspectives
Vijay Kumar Panthi, Kathryn E. Fairfull‐Smith, Nazrul Islam
Journal of Drug Delivery Science and Technology (2024) Vol. 94, pp. 105517-105517
Open Access | Times Cited: 6
Design, green synthesis, and quorum sensing quenching potential of novel 2-oxo-pyridines containing a thiophene/furan scaffold and targeting a LasR gene on P. aeruginosa
Yousry A. Ammar, Ahmed Ragab, M.A. Migahed, et al.
RSC Advances (2023) Vol. 13, Iss. 39, pp. 27363-27384
Open Access | Times Cited: 14
In vitro activity of cefiderocol against Gram-negative pathogens isolated from people with cystic fibrosis and bronchiectasis
Michael M. Tunney, J.S. Elborn, C. McLaughlin, et al.
Journal of Global Antimicrobial Resistance (2024) Vol. 36, pp. 407-410
Open Access | Times Cited: 5
Mucosal-adapted bacteriophages as a preventive strategy for a lethal Pseudomonas aeruginosa challenge in mice
Luiz Felipe Leomil Coelho, Mateus de Souza Terceti, Sergio Pereira Lima Neto, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access
Policy in Practice: Cystic Fibrosis Australia and Phage Australia survey: understanding clinical needs and attitudes towards phage therapy in the CF community
Stephanie Lynch, Holly Sinclair, Ameneh Khatami, et al.
Deleted Journal (2025) Vol. 2, Iss. 1
Closed Access
Menadione as Antibiotic Adjuvant Against P. aeruginosa: Mechanism of Action, Efficacy and Safety
Kristela Shehu, Marc Schneider, Annette Kraegeloh
Antibiotics (2025) Vol. 14, Iss. 2, pp. 163-163
Open Access
Broad-spectrum antimicrobial properties of linalool: supporting its pharmacological use in chronic wound infections by pathogens within the ESKAPE group and polymicrobial biofilms
Akshatha Rai, Yuvarajan Subramaniyan, Fida Fathima, et al.
World Journal of Microbiology and Biotechnology (2025) Vol. 41, Iss. 3
Closed Access
Pathogen Partnerships or Power Struggles? Pseudomonas aeruginosa, and Staphylococcus aureus Dynamics in Cystic Fibrosis
N. Saleh, Esraa S F Sudan, Sara Mohamed, et al.
Current Microbiology (2025) Vol. 82, Iss. 6
Closed Access
Unveiling the molecular epidemiology of Pseudomonas aeruginosa in lung infections among cystic fibrosis patients in the Brazilian Amazon
Maria Isabel Montoril Gouveia, Edilene do Socorro Nascimento Falcão Sarges, Herald Souza dos Reis, et al.
BMC Microbiology (2025) Vol. 25, Iss. 1
Open Access
Optimizing in vitro phage-ciprofloxacin combination formulation for respiratory therapy of multi-drug resistant Pseudomonas aeruginosa infections
Qixuan Hong, Rachel Yoon Kyung Chang, Omar Assafiri, et al.
International Journal of Pharmaceutics (2024) Vol. 652, pp. 123853-123853
Open Access | Times Cited: 3
Valorization of biomass to activated carbon for wound dressing applications: Recent trends and future challenges
P. Balasubramanian, Mari Selvam S.
Bioresource Technology Reports (2023) Vol. 23, pp. 101562-101562
Closed Access | Times Cited: 4
Tetramerization is essential for the enzymatic function of the Pseudomonas aeruginosa virulence factor UDP-glucose pyrophosphorylase
Larissa Dirr, Sven Cleeves, Isabel Ramón Roth, et al.
mBio (2024) Vol. 15, Iss. 4
Open Access | Times Cited: 1
Assessing the Potential of N-Butyl-l-deoxynojirimycin (l-NBDNJ) in Models of Cystic Fibrosis as a Promising Antibacterial Agent
Anna Esposito, Alice S. Rossi, Maria Rosaria Stabile, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 6, pp. 1807-1822
Open Access | Times Cited: 1
Cystic fibrosis management in pediatric population—from clinical features to personalized therapy
Alice Azoicăi, Ancuța Lupu, Laura Mihaela Trandafir, et al.
Frontiers in Pediatrics (2024) Vol. 12
Open Access | Times Cited: 1
Investigating the Protective Effect of Camphene-Conjugated Zinc Oxide Nanoparticles Against Pseudomonas aeruginosa Infection in Danio rerio
Praveen Kumar Issac, Kadhirmathiyan Velumani, Vikhram Ravi, et al.
BioNanoScience (2024) Vol. 14, Iss. 5, pp. 4942-4955
Closed Access | Times Cited: 1
Ceftolozane/Tazobactam for the Treatment of Adults With Cystic Fibrosis: Results From a French Prospective Cohort Study
Pierre–Régis Burgel, Xavier Bourge, Carole Mackosso, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 8
Open Access | Times Cited: 1
Livestock associated Staphylococcus aureus in cystic fibrosis patients in Spain: detection of MRSA and MSSA CC398
Paula Eguizábal, Ana Isabel López‐Calleja, Antonina Arias, et al.
Microbial Pathogenesis (2024) Vol. 197, pp. 107016-107016
Open Access | Times Cited: 1
In vitro activity of cefiderocol against Pseudomonas aeruginosa isolated from cystic fibrosis patients
Marguerite L. Monogue, Dhara Desai, Christine Pybus, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 6
Open Access | Times Cited: 2
Polymerized cyclodextrin microparticles for sustained antibiotic delivery in lung infections
Tracey L. Bonfield, S. Zuckerman, Morgan T. Sutton, et al.
Journal of Biomedical Materials Research Part A (2024) Vol. 112, Iss. 8, pp. 1305-1316
Open Access
Cystic Fibrosis Australia and Phage Australia survey: Understanding clinical needs and attitudes towards phage therapy in the CF community
Stephanie Lynch, Holly Sinclair, Ameneh Khatami, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Page 1 - Next Page

Scroll to top